Salivary CD44, Total Protein ID Recurrence Risk in Head and Neck Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 22, 2024 -- Elevated salivary levels of CD44 and total protein (TP) can identify head and neck cancer patients with an increased risk for cancer recurrence, according to a study published online Aug. 15 in JAMA Otolaryngology-Head and Neck Surgery.
Elizabeth J. Franzmann, M.D., from the University of Miami Health System and Jackson Memorial Hospital, and colleagues conducted a multi-institutional nonrandomized clinical trial testing a novel diagnostic/screening assay to examine whether soluble CD44 and TP are useful for monitoring head and neck cancer recurrence in a point-of-care (POC) test. Oral rinses were collected at pretreatment baseline and at three, six, 12, and 18 months after completion of therapy. To define disease status, participants were followed for three years.
Among the 172 patients who were enrolled, the researchers found an association for tumor site with test results at baseline; a higher baseline positive POC test rate was seen for patients with oral cavity cancer versus oropharyngeal cancer (92.2 versus 77.3 percent). A higher CD44 level showed a significant association with a higher risk for recurrence using Cox regression models with CD44 or TP level as a time-varying covariate (hazard ratio, 1.06). Higher CD44 and TP levels were associated with increased hazard ratios of recurrence of 1.13 and 3.51, respectively, in a multivariate adjusted analysis.
“Our study suggests biomarker detection in saliva collected from an oral rinse after initial treatment offers potential to readily assess recurrence risk,” Franzmann said in a statement. “Elevated levels of either of two biomarkers were associated with disease return.”
One author disclosed ties to the biopharmaceutical industry and is inventor of the intellectual property used in the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Harmonic-to-Noise Ratio Could Identify Early Laryngeal Cancer
TUESDAY, Aug. 12, 2025 -- Acoustic features, specifically harmonic-to-noise ratio (HNR) and its variability, could be promising for early detection of vocal fold lesions...
440 Deaths in Los Angeles County Reported Due to January 2025 Wildfires
TUESDAY, Aug. 12, 2025 -- An estimated 440 deaths from Jan. 5 to Feb. 1, 2025, in Los Angeles County were attributable to the Los Angeles wildfires, according to a research letter...
Public Believes Dermatologic Side Effects From Cancer Treatment Are Common
TUESDAY, Aug. 12, 2025 -- Most individuals living in underserved communities believe that dermatologic side effects (DSEs) from anticancer therapies (ACTs) occur at high rates...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.